A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects



Status:Recruiting
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 55
Updated:10/3/2013
Start Date:January 2013
Contact:Medical Monitor
Email:medicalinfo@vrtx.com
Phone:617-341-6777

Use our guide to learn which trials are right for you!

A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects


The purpose of this study is to examine the drug-drug interaction effects of ciprofloxacin,
itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with
ivacaftor as well as to evaluate the potential effects of lumacaftor in combination with
ivacaftor on lung function.


Inclusion Criteria:

- Male and female subjects must be between the ages of 18 and 55 years, inclusive

- Body mass index (BMI) of 18 to 31 kg/m2, inclusive, and a total body weight >50 kg.

Exclusion Criteria:

- History of any illness that, in the opinion of the investigator, might confound the
results of the study or pose an additional risk in administering study drug(s) to the
subject. This may include, but is not limited to, a history of relevant drug or food
allergies; history of cardiovascular or central nervous system disease; history or
presence of clinically significant pathology; or history of mental disease.

- History of febrile illness within 5 days before the first dose.

- History of Gilbert's syndrome

- Abnormal renal function as defined at screening

- Blood donation of approximately 1 pint (500 mL) within 56 days before study drug
administration

- Treatment with an investigational drug within 30 days or 5 half-lives (or as
determined by the local requirements, whichever is longer) preceding the first dose
of study drug

- Known hypersensitivity or prior adverse reaction to ciprofloxacin, or any member of
the quinolone class of antimicrobial agents (Cohort 1 only); itraconazole, or to any
of the other azoles (Cohort 2 only); rifampin, or to any of the rifamycins (Cohort 3
only)
We found this trial at
1
site
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials